Emerging Targeted Therapy for Bladder Cancer
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 35 (3) , 585-596
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceutica
- Sanofi
- Pfizer
- Meso Scale Diagnostics
- Bristol-Myers Squibb
- Astellas Pharma US
- AstraZeneca
- Roche
This publication has 31 references indexed in Scilit:
- Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.Journal of Clinical Oncology, 2020
- ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.Journal of Clinical Oncology, 2020
- FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.Journal of Clinical Oncology, 2020
- Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2019
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma withFGFR3AlterationsCancer Discovery, 2018
- FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).Journal of Clinical Oncology, 2018
- A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursBritish Journal of Cancer, 2017
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation SequencingClinical Cancer Research, 2016
- Genomic Characterization of Upper Tract Urothelial CarcinomaEuropean Urology, 2015
- Roles of Fibroblast Growth Factor Receptors in CarcinogenesisMolecular Cancer Research, 2010